The JSC Subgroup, via the HTA secretariat, should share with the selected individual experts the briefing package and should give them the opportunity to provide input on the joint scientific consultation. The HTA secretariat should invite the selected individual experts to the meeting for an exchange of views with the health technology developer referred to in Article 18(7) and (8) of Regulation (EU) 2021/2282. At any time during the joint scientific consultation, the JSC Subgroup should have the possibility to consult stakeholder organisations. In particular, such consultation should entail a more general input on the disease and therapeutic area from patient organisations, healthcare professional organisations or clinical and learned societies and should be conducted via the members of the stakeholder network. Such consultation must not disclose the actual medicinal product subject to the joint scientific consultation.
Recital 10, Regulation (EU) 2024/3169
In forcesince 18 Dec 2024